Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01319578 · ClinicalTrials.gov registry record · NA
PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum
A NA study, sponsored by Denver Nephrologists, P.C..
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT01319578: Completed NA study, sponsored by Denver Nephrologists, P.C..
NCT01319578 is a NA study that has completed, run by Denver Nephrologists, P.C.. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01319578, a NA study, has completed, sponsored by Denver Nephrologists, P.C..
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The specific purpose of this study is to describe the characteristics of the K2CG chewing gum, specifically as it relates to duration of gum chewing (exposure), timing of gum chewing in relation to a meal, and dose of K2CG chewing gum.
Primary Outcome
patients will be assigned to treatment arms of varying chewing duration fasting and the total phosphorous bound per piece of chewing gum will be assessed. each patient will recieve (in random order) gum with placebo, 20 mg, 40 mg, and 60 mg chitosan content
Interventions
- OTHER K2CG chewing gum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-08 |
| Phase | NA |
What the finished NCT01319578 record still lists
NCT01319578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which K2CG chewing gum is the first listed.
NCT01319578 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01319578 about?
NCT01319578 is a clinical study titled "PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum". The specific purpose of this study is to describe the characteristics of the K2CG chewing gum, specifically as it relates to duration of gum chewing (exposure), timing of gum chewing in relation to a meal, and dose of K2CG chewing gum.
What is the current status of trial NCT01319578?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2011-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01319578?
The interventions under investigation include: K2CG chewing gum (OTHER).
Who is sponsoring clinical trial NCT01319578?
This trial is sponsored by Denver Nephrologists, P.C., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01319578's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia